Quarterly ResultMay 7, 2026, 07:42 AM
Lantheus Q1 Revenue $377.3M, GAAP EPS $1.80; FDA Approvals
AI Summary
Lantheus Holdings, Inc. reported Q1 2026 financial results, with worldwide revenue increasing 1.2% to $377.3 million. GAAP fully diluted earnings per share significantly rose 76.5% to $1.80, while adjusted fully diluted earnings per share decreased 4.6% to $1.46. The company also announced FDA approval for PYLARIFY TruVu, with a phased launch planned for Q4 2026, and tentative FDA approval for Lutetium Lu 177 Dotatate (PNT2003). Lantheus reaffirmed its full-year 2026 financial guidance and completed the divestiture of its SPECT business.
Key Highlights
- FDA approved PYLARIFY TruVu, with phased launch planned for Q4 2026.
- FDA granted tentative approval for Lutetium Lu 177 Dotatate (PNT2003).
- Q1 2026 worldwide revenue increased 1.2% to $377.3 million.
- GAAP fully diluted EPS rose 76.5% to $1.80 for Q1 2026.
- Adjusted fully diluted EPS decreased 4.6% to $1.46 for Q1 2026.
- PYLARIFY sales decreased 6.5% to $240.9 million.
- DEFINITY sales increased 6.8% to $84.6 million.
- Reaffirmed FY2026 revenue guidance of $1.4B-$1.45B and adjusted EPS of $5.00-$5.25.
Price Impact
More from LNTH